BioHarvest SciencesBHST
BHST logo
Fair Value
US$13.67
Share price10 Dec
US$2.2683.5% undervalued intrinsic discount
Loading
1Y-71.39%
7D2.96%

Plant Based CDMO Expansion And Health Pros Network Will Drive Long Term Upside

Analyst Consensus Target compiles analysts opinions to create narratives on stocks using the Analysts Consensus Price Target, forecasted revenue and earnings figures, as well as the transcripts of earnings calls.

Published
10 Dec 25
Views
4
Not Invested

Fair Value vs Share Price

US$13.67
vs US$2.2683.5% undervalued intrinsic discount
PastFuture-13m170m20162018202020222024202520262028Revenue US$170.0mEarnings US$24.3m
73.2%
Revenue growth
14.3%
Profit margin

Recent News & Updates

No updates

Recent updates

No updates

Stay ahead on BioHarvest Sciences

  • Fair value estimate changes
  • Narrative and analyst updates
  • Key company announcements

Company analysis

High growth potential with adequate balance sheet.

Market capUS$51.2m
PB2.2x
Estimated Growth29.0%
Dividend YieldN/A
Full analysis

CEO & management

Zaki Rakib
CEO
2.9yrs
CEO Tenure

Operates as a biotechnology company in Israel and the United States.